KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Edwards Lifesciences (EW) Net Margin (2016 - 2025)

Edwards Lifesciences has reported Net Margin over the past 17 years, most recently at 1.72% for Q4 2025.

  • Quarterly results put Net Margin at 1.72% for Q4 2025, down 112.0% from a year ago — trailing twelve months through Dec 2025 was 0.22% (down 5077.0% YoY), and the annual figure for FY2025 was 0.22%, down 5077.0%.
  • Net Margin for Q4 2025 was 1.72% at Edwards Lifesciences, up from 0.13% in the prior quarter.
  • Over the last five years, Net Margin for EW hit a ceiling of 199.89% in Q3 2024 and a floor of 0.51% in Q1 2025.
  • Median Net Margin over the past 5 years was 14.72% (2023), compared with a mean of 26.76%.
  • Biggest five-year swings in Net Margin: skyrocketed 19596bps in 2024 and later crashed -20002bps in 2025.
  • Edwards Lifesciences' Net Margin stood at 25.22% in 2021, then soared by 268bps to 92.67% in 2022, then tumbled by -97bps to 2.89% in 2023, then dropped by -2bps to 2.84% in 2024, then plummeted by -39bps to 1.72% in 2025.
  • The last three reported values for Net Margin were 1.72% (Q4 2025), 0.13% (Q3 2025), and 0.29% (Q2 2025) per Business Quant data.